Loading...
•
Sep 30, 2022
Allogene Q3 2022 Earnings Report
Allogene Therapeutics reported financial results for the third quarter of 2022 and announced an Investor R&D Showcase.
Key Takeaways
Allogene Therapeutics reported the initiation of their Phase 2 ALPHA2 trial and ended the third quarter with $637 million in cash, cash equivalents and investments. The company will host a Research & Development Showcase on November 29, 2022.
Initiated the Industry’s First Allogeneic CAR T Phase 2 Trial (ALPHA2 Trial).
Readiness activities underway for initiation of the EXPAND Trial.
Company to Host Research & Development Showcase on November 29, 2022.
Ended Third Quarter with $637 Million in Cash, Cash Equivalents and Investments.
Allogene
Allogene
Forward Guidance
The Company expects full year GAAP Operating Expenses to be slightly below the low end of its prior guidance of $360 million and $390 million, including estimated non-cash stock-based compensation expense of $90 million to $100 million and excluding any impact from potential business development activities. Cash burn for 2022 is expected to be less than $250 million.